Hansoh Pharma Receives IND Acceptance for Two Novel Biologics, HS-20093 and HS-20089

On July 15, the official website of the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) indicated that the clinical trial applications for therapeutic biologics HS-20093 and HS-20089, submitted by Hansoh Pharma as Class 1 new drugs, have been accepted for review. Since 2020, Hansoh Pharma has had four biologics applications under CDE review, including one pending production approval, one in Phase I clinical trials, and two at the IND stage.